Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16017457 | 1.00 | TP53 (0.38) | TP53CYP26A1SIRT2MMP8TSHR | |
| SCHEMBL16017455 | 0.87 | NPSR1 (0.36) | SIRT2MAPT | |
| SCHEMBL16019986 | 0.86 | SCN9A (0.43) | TP53TSHRMAPT | |
| SCHEMBL16017454 | 0.81 | MAPT (0.34) | SIRT2MMP8TSHRGABRA2GABRB2 | |
| SCHEMBL16019962 | 0.79 | AAK1 (0.38) | TP53TSHRMAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL689021 | 0.77 | LMNA (0.44) | TP53TSHRMAPTLMNASMN1; SMN2 | |
| SCHEMBL1562700 | 0.74 | MAPT (0.45) | TP53TSHRGABRA2GABRB2MAPT | |
| SCHEMBL8720494 | 0.74 | GAA (0.39) | TSHRMAPTL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL23532128 | 0.72 | CYP11B1 (0.36) | TP53SIRT2TSHRLMNASMN1; SMN2 | |
| SCHEMBL27405017 | 0.72 | POLB (0.36) | MAPTL3MBTL1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256698-A1 | CATHEPSIN INHIBITORS | VIROBAY, INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256698-A1 | CATHEPSIN INHIBITORS | CTSF, CTSZ, CTSV | TP53 581/4885CYP26A1 3051/4885SIRT2 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.